NOVAVAX INC Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NOVAVAX INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NOVAVAX INC for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 279.20 | 73 | 20,382 | 2,811 | 2.9 K to 2.8 K (-2.53 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 278.27 | 65 | 18,088 | 2,884 | 2.9 K to 2.9 K (-2.20 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 276.23 | 32 | 8,839 | 2,949 | 3 K to 2.9 K (-1.07 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 274.63 | 48 | 13,182 | 2,981 | 3 K to 3 K (-1.58 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 273.61 | 67 | 18,332 | 3,029 | 3.1 K to 3 K (-2.16 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 272.43 | 205 | 55,848 | 3,096 | 3.3 K to 3.1 K (-6.21 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 271.16 | 110 | 29,827 | 3,301 | 3.4 K to 3.3 K (-3.22 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 269.94 | 319 | 86,109 | 3,411 | 3.7 K to 3.4 K (-8.55 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 269.23 | 678 | 182,536 | 3,730 | 4.4 K to 3.7 K (-15.38 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 268.19 | 268 | 71,875 | 4,408 | 4.7 K to 4.4 K (-5.73 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 266.68 | 128 | 34,135 | 4,676 | 4.8 K to 4.7 K (-2.66 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 265.53 | 361 | 95,854 | 4,804 | 5.2 K to 4.8 K (-6.99 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 264.09 | 80 | 21,127 | 5,165 | 5.2 K to 5.2 K (-1.53 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 61,281 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 71,876 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 17,423 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 7,473 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 2,480 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 262.70 | 2,275 | 597,643 | 5,245 | 7.5 K to 5.2 K (-30.25 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 262.70 | 110 | 28,897 | 7,520 | 7.6 K to 7.5 K (-1.44 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 4,819 | 28,673 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 296.59 | 66 | 19,575 | 2,811 | 2.9 K to 2.8 K (-2.29 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 294.05 | 13 | 3,823 | 2,877 | 2.9 K to 2.9 K (-0.45 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 291.57 | 413 | 120,419 | 2,890 | 3.3 K to 2.9 K (-12.50 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 289.89 | 125 | 36,236 | 3,303 | 3.4 K to 3.3 K (-3.65 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 288.80 | 9 | 2,599 | 3,428 | 3.4 K to 3.4 K (-0.26 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 287.41 | 147 | 42,249 | 3,437 | 3.6 K to 3.4 K (-4.10 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 286.26 | 148 | 42,367 | 3,584 | 3.7 K to 3.6 K (-3.97 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 285.30 | 59 | 16,833 | 3,732 | 3.8 K to 3.7 K (-1.56 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 284.25 | 1,204 | 342,235 | 3,791 | 5 K to 3.8 K (-24.10 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 283.43 | 955 | 270,678 | 4,995 | 6 K to 5 K (-16.05 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 282.13 | 653 | 184,233 | 5,950 | 6.6 K to 6 K (-9.89 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 281.64 | 522 | 147,015 | 6,603 | 7.1 K to 6.6 K (-7.33 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 280.71 | 156 | 43,790 | 7,125 | 7.3 K to 7.1 K (-2.14 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 278.98 | 236 | 65,840 | 7,281 | 7.5 K to 7.3 K (-3.14 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 277.09 | 377 | 104,461 | 7,517 | 7.9 K to 7.5 K (-4.78 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 275.83 | 129 | 35,582 | 7,894 | 8 K to 7.9 K (-1.61 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 274.80 | 225 | 61,829 | 8,023 | 8.2 K to 8 K (-2.73 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 273.40 | 137 | 37,455 | 8,248 | 8.4 K to 8.2 K (-1.63 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 272.42 | 138 | 37,593 | 8,385 | 8.5 K to 8.4 K (-1.62 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 5.95 | 384 | 2,285 | 12,267 | |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 5.95 | 2,084 | 12,400 | 66,667 | |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 46.00 | 521 | 23,966 | 11,986 | |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 27.60 | 417 | 11,509 | 4,592 | |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 324.50 | 194 | 62,953 | 287 | 481 to 287 (-40.33 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Payment of Exercise | F | 290.18 | 182 | 52,813 | 481 | 663 to 481 (-27.45 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | D | 290.18 | 8 | 2,321 | 663 | 671 to 663 (-1.19 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 5.95 | 384 | 2,285 | 671 | 287 to 671 (+133.80 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 298.80 | 25 | 7,470 | 287 | 312 to 287 (-8.01 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 297.82 | 30 | 8,935 | 312 | 342 to 312 (-8.77 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 296.96 | 104 | 30,884 | 342 | 446 to 342 (-23.32 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 296.01 | 238 | 70,451 | 446 | 684 to 446 (-34.80 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 295.05 | 625 | 184,404 | 684 | 1.3 K to 684 (-47.75 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 293.96 | 405 | 119,054 | 1,309 | 1.7 K to 1.3 K (-23.63 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 292.91 | 272 | 79,670 | 1,714 | 2 K to 1.7 K (-13.70 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 291.79 | 117 | 34,139 | 1,986 | 2.1 K to 2 K (-5.56 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 290.86 | 57 | 16,579 | 2,103 | 2.2 K to 2.1 K (-2.64 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 289.45 | 55 | 15,920 | 2,160 | 2.2 K to 2.2 K (-2.48 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 287.03 | 30 | 8,611 | 2,215 | 2.2 K to 2.2 K (-1.34 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 284.82 | 25 | 7,121 | 2,245 | 2.3 K to 2.2 K (-1.10 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 283.50 | 1,020 | 289,171 | 2,270 | 3.3 K to 2.3 K (-31.00 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 282.00 | 19 | 5,358 | 3,290 | 3.3 K to 3.3 K (-0.57 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 5.95 | 2,084 | 12,400 | 3,309 | 1.2 K to 3.3 K (+170.12 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 46.00 | 521 | 23,966 | 1,225 | 704 to 1.2 K (+74.01 %) |
| Feb 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 27.60 | 417 | 11,509 | 704 | 287 to 704 (+145.30 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 5.95 | 8,249 | 49,082 | 66,001 | |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 46.00 | 2,080 | 95,680 | 9,591 | |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 27.60 | 2,085 | 57,546 | 4,592 | |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 27.00 | 2,214 | 59,778 | 0 | |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 27.00 | 394 | 10,638 | 0 | |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 243.25 | 3,754 | 913,161 | 275 | 4 K to 275 (-93.17 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 242.20 | 2,200 | 532,833 | 4,029 | 6.2 K to 4 K (-35.32 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 241.51 | 3,331 | 804,459 | 6,229 | 9.6 K to 6.2 K (-34.84 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 240.43 | 4,294 | 1,032,399 | 9,560 | 13.9 K to 9.6 K (-30.99 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 239.04 | 1,443 | 344,938 | 13,854 | 15.3 K to 13.9 K (-9.43 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 5.95 | 8,249 | 49,082 | 15,297 | 7 K to 15.3 K (+117.04 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 46.00 | 2,080 | 95,680 | 7,048 | 5 K to 7 K (+41.87 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 27.60 | 2,085 | 57,546 | 4,968 | 2.9 K to 5 K (+72.32 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 27.00 | 2,214 | 59,778 | 2,883 | 669 to 2.9 K (+330.94 %) |
| Feb 03 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 27.00 | 394 | 10,638 | 669 | 275 to 669 (+143.27 %) |